Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion Defends PAH Franchise With Generics And Second-Generation Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

With patent erosion starting for Tracleer, its largest-selling product, Actelion outlines further details of its short- and medium-term strategy to reduce its reliance on the billion-dollar PAH therapy.

You may also be interested in...



European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation

Europe's leading biotech Actelion plans to cut 5% of its workforce, while Sanofi considers a major overhaul of its R&D sites in France, as competitive pressures and the European debt crisis continue.

Actelion's Macitentan Meets Primary Endpoint In Pivotal SERAPHIN Study, Approval Filings Expected In Fourth Quarter

Swiss biotech Actelion expects to submit its next-generation PAH therapy macitentan for approval in the fourth quarter of this year, giving it time to replace current top-selling product Tracleer before that product loses patent protection in 2015.

Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning

REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel